Follow
Susan Halabi, PhD, FSCT, FASA, FASCO
Susan Halabi, PhD, FSCT, FASA, FASCO
Verified email at duke.edu - Homepage
Title
Cited by
Cited by
Year
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology 26 (7), 1148-1159, 2008
24052008
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
RS Sandler, S Halabi, JA Baron, S Budinger, E Paskett, R Keresztes, ...
New England Journal of Medicine 348 (10), 883-890, 2003
14922003
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402-1418, 2016
13452016
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
PW Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, ...
Journal of Clinical Oncology 17 (8), 2506-2506, 1999
11641999
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ...
Journal of Clinical Oncology 26 (33), 5422-5428, 2008
11572008
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11391999
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ...
Journal of clinical oncology 28 (13), 2137-2143, 2010
10642010
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi, EJ Small, PW Kantoff, MW Kattan, EB Kaplan, NA Dawson, ...
Journal of Clinical Oncology 21 (7), 1232-1237, 2003
8122003
Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial
TK Choueiri, S Halabi, BL Sanford, O Hahn, MD Michaelson, MK Walsh, ...
Journal of Clinical Oncology 35 (6), 591-597, 2017
8012017
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
EJ Small, S Halabi, NA Dawson, WM Stadler, BI Rini, J Picus, P Gable, ...
Journal of clinical oncology 22 (6), 1025-1033, 2004
6552004
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials
BF Cole, RF Logan, S Halabi, R Benamouzig, RS Sandler, MJ Grainge, ...
JNCI: Journal of the National Cancer Institute 101 (4), 256-266, 2009
5722009
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
RA Kyle, GC Yee, MR Somerfield, PJ Flynn, S Halabi, S Jagannath, ...
Journal of Clinical Oncology 25 (17), 2464-2472, 2007
5262007
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
5232018
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate …
WK Kelly, S Halabi, M Carducci, D George, JF Mahoney, WM Stadler, ...
Journal of Clinical Oncology 30 (13), 1534-1540, 2012
5052012
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
S Halabi, CY Lin, WK Kelly, KS Fizazi, JW Moul, EB Kaplan, MJ Morris, ...
Journal of Clinical Oncology 32 (7), 671-677, 2014
4962014
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin, B Rajeshkumar, S Halabi, CP Werner, BA Woda, J Picus, ...
Journal of clinical oncology 21 (14), 2673-2678, 2003
4892003
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer
S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ...
Journal of clinical oncology 34 (14), 1652-1659, 2016
4252016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ...
The Lancet Oncology 17 (3), 378-388, 2016
4182016
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780
DM Savarese, S Halabi, V Hars, WL Akerley, ME Taplin, PA Godley, ...
Journal of Clinical Oncology 19 (9), 2509-2516, 2001
4102001
Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer
W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ...
Journal of Clinical Oncology 35 (27), 3097-3104, 2017
4062017
The system can't perform the operation now. Try again later.
Articles 1–20